Jun 11, 2014 by Michael Douglass and Dave WilliamsonAllergan Rejects Valeant Again: What's Next?Allergan's board unanimously turned down Valeant's latest offer. What should investors be watching for next?
Jun 11, 2014 by Michael Douglass and Jason MoserDown 18%: Is Orexigen a Bad News Buy?The stock cratered 18% on a delayed FDA decision...but was the sell-off overdone?
Jun 10, 2014 by Michael Douglass and Dave WilliamsonUp 37%: Can Receptos Compete With Novartis?Receptos shareholders had a great day today -- how does the stock measure up in the multiple sclerosis industry?
Jun 10, 2014 by Michael Douglass and Matt TrogdonUp 58%: Should You Buy Achillion Pharmaceuticals Today?The stock's having a great day -- time to buy?
Jun 9, 2014 by Michael Douglass and Dave WilliamsonWhy Investors Are Wrong about AriadMany people are invested in Ariad on the hopes that all the bad news has been priced in -- here's why that might be a mistake.
Jun 8, 2014 by Michael Douglass and Dave WilliamsonThe Repercussions of Medicare's New Hepatitis C PushCould Medicare's new hepatitis c screening coverage make a big difference to investors?
Jun 8, 2014 by Michael Douglass and Dave WilliamsonBig Data's Big Future in Health CareHow big data could make a huge difference in health and profitability.
Jun 7, 2014 by Michael Douglass and Dave WilliamsonHow Apple Is Leading Health Care's Wearables RevolutionApple made health care news last week with this exciting announcement. Watch below to find out more.
Jun 7, 2014 by Michael Douglass and Dave WilliamsonA Doctor in Every Home: The Future Is NowHow WellPoint is pioneering telehealth (and how others may follow).
Jun 5, 2014 by Michael Douglass22% Pop: 3 Key TakeawaysBio-Reference Labs had a great day -- are even greater days ahead?
Jun 5, 2014 by Michael Douglass and Dave WilliamsonUp 12%: Halozyme Therapeutics Is Back to WorkHalozyme had a great day today -- so what's next?
Jun 5, 2014 by Michael Douglass and Dave WilliamsonDown 7%: Was Rite Aid's Sell-Off Overdone?Rite Aid had a rough day. Was the drop too much?
Jun 3, 2014 by Michael Douglass and Dave Williamson1 Biotech Steamrolling the CompetitionThis biotech is on a roll -- and new data help keep it going.
Jun 2, 2014 by Michael Douglass and Dave WilliamsonUp 7%: Ariad Gets Good News at LastAriad shares jumped today after some positive news from the ASCO conference. Watch below to find out more!
Jun 2, 2014 by Michael Douglass and Dave WilliamsonDown 7%: Clovis' ASCO NewsClovis shares lost 7% today on ASCO news. Watch below to find out why.
Jun 1, 2014 by Michael Douglass and Dave WilliamsonShockingly Accurate: The Newest Medical Device Sniffing Out CancerIt turns out that dogs could be an incredible asset to the cancer detection fight. But what can investors do?
May 31, 2014 by Michael Douglass and Dave WilliamsonIs Obamacare Fueling More Buyouts?Could Centene and WellCare Health Plans be the next health care companies to get bought?
May 30, 2014 by Michael Douglass and Dave WilliamsonUp 13%: NPS Pharmaceuticals Buyout RumorYet another buyout candidate -- and this time with Shire involved as a potential acquirer.
May 30, 2014 by Michael Douglass and Dave WilliamsonDoes Walgreen + Alliance Boots Make Sense?Should Walgreen purchase the remainder of the company in February?
May 29, 2014 by Michael Douglass and Dave Williamson#1 Draft Pick: A Sure-Fire Slam Dunk?One analyst's pick for what could be the best drug in development.
